Founder of Molecular Health AG, Lion Bioscience AG and Molecular Health GmbH, Friedrich von Bohlen und Halbach is a German entrepreneur and businessperson who has been at the helm of 13 different companies and currently holds the position of Chairman-Supervisory Board at Apogenix AG, Chairman & Chief Executive Officer for Molecular Health AG, Executive Chairman for Molecular Health, Inc. and Chief Executive Officer & Managing Director at Molecular Health GmbH (both are subsidiaries of Molecular Health AG), Chairman-Supervisory Board for Novaliq GmbH, Managing Director at dievini Verwaltungs GmbH and Managing Director at dievini Hopp BioTech holding GmbH & Co. KG. Dr. Von Bohlen und Halbach is also Co-Chairman-Evaluation Board at Wyss Translational Center Zurich and on the board of 10 other companies.
In the past he was Member-Supervisory Board at Agennix AG and Chief Executive Officer of GPC Biotech AG (a subsidiary of Agennix AG), Project Manager-Research & Development at Fresenius SE & Co. KGaA, Chairman of Private Life BioMed AG, Chairman-Supervisory Board at Heidelberg Pharma AG, Chairman-Supervisory Board of Lion Bioscience AG, Chief Executive Officer of Wasag Chemie AG and Professor-Information Sciences at Fachhochschule Ludwigshafen am Rhein.
He received a doctorate from Swiss Federal Institute of Technology.